Shots:  Pheast Therapeutics is redefining innate immunity in oncology with PHST001, an anti-CD24 macrophage checkpoint inhibitor engineered to overcome the limitations of earlier macrophage-targeted therapies and unleash a powerful anti-tumor immune response.  At AACR 2026, PHST001 delivered encouraging early clinical signals with favorable tolerability, clear immune activation, and promising anti-tumor responses across heavily pretreated solid tumor…